SCOPUS 정보 검색 플랫폼

Breast Cancer Research

Volumn 9, Issue 2, 2007, Pages

The ethics of CYP2D6 testing for patients considering tamoxifen

(2) Hartman, Anne Renee a Helft, Paul b

a Division of Hematology/Oncology ^* (United States)

b INDIANA UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P450 2D6; TAMOXIFEN;

ARTICLE; BIOETHICS; BREAST TUMOR; ETHICS; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; GENOTYPE; HUMAN; METHODOLOGY; PHARMACOGENETICS; POSTMENOPAUSE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOETHICS; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC SCREENING; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 34250199706 PISSN: 14655411 EISSN: 1465542X Source Type: Journal
DOI: 10.1186/bcr1663 Document Type: Note

Times cited : (14)

References (8)

1
- 0346602691
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
- Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
- (2003) J Natl Cancer Inst , vol.95 , pp. 1758-1764
- Stearns, V.¹ Johnson, M.D.² Rae, J.M.³ Morocho, A.⁴ Novielli, A.⁵ Bhargava, P.⁶ Hayes, D.F.⁷ Desta, Z.⁸ Flockhart, D.A.⁹

2
- 19944434201
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
- Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
- (2005) J Natl Cancer Inst , vol.97 , pp. 30-39
- Jin, Y.¹ Desta, Z.² Stearns, V.³ Ward, B.⁴ Ho, H.⁵ Lee, K.H.⁶ Skaar, T.⁷ Storniolo, A.M.⁸ Li, L.⁹ Araba, A.¹⁰

3
- 30544454432
- Pharmacogenomic determinants of outcome with tamoxifen therapy: Findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52
- Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al. Pharmacogenomic determinants of outcome with tamoxifen therapy: Findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. Breast Cancer Res Treat 2004, (Suppl 1):88LS35.
- (2004) Breast Cancer Res Treat , Issue.SUPPL. 1
- Goetz, M.P.¹ Rae, J.M.² Suman, V.J.³ Safgren, S.L.⁴ Ames, M.M.⁵ Visscher, D.W.⁶ Reynolds, C.⁷ Couch, F.J.⁸ Lingle, W.L.⁹ Flockhart, D.A.¹⁰

4
- 33847034287
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
- 10.1007/s10549-006-9428-0, 17115111
- Knox SK, Ingle JN, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilbourn RM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101:113-121. 10.1007/s10549-006-9428-0, 17115111.
- (2007) Breast Cancer Res Treat , vol.101 , pp. 113-121
- Knox, S.K.¹ Ingle, J.N.² Suman, V.J.³ Rae, J.M.⁴ Safgren, S.L.⁵ Ames, M.M.⁶ Visscher, D.W.⁷ Reynolds, C.⁸ Couch, F.J.⁹ Lingle, W.L.¹⁰ Weinshilbourn, R.M.¹¹

5
- 48249083218
- Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment
- Grabinski JL, Smith LS, Chrisholm GB, Drengler R, Rodriguez GI, Lang AS, Katler SP, Garner AM, Fichtel LM. Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment. J Clin Oncol (Meeting Abstracts) 2006, 24:506.
- (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 506
- Grabinski, J.L.¹ Smith, L.S.² Chrisholm, G.B.³ Drengler, R.⁴ Rodriguez, G.I.⁵ Lang, A.S.⁶ Katler, S.P.⁷ Garner, A.M.⁸ Fichtel, L.M.⁹

6
- 80051554892
- National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (V.2-2006)
- National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (V.2-2006). , http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf

7
- 20044382779
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
- Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
- (2005) J Clin Oncol , vol.23 , pp. 619-629
- Winer, E.P.¹ Hudis, C.² Burstein, H.J.³ Wolff, A.C.⁴ Pritchard, K.I.⁵ Ingle, J.N.⁶ Chlebowski, R.T.⁷ Gelber, R.⁸ Edge, S.B.⁹ Gralow, J.¹⁰

8
- 80051569802
- Phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer
- Suppression of Ovarian Function Trial (SOFT)
- Suppression of Ovarian Function Trial (SOFT) Phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. Suppression of Ovarian Function Trial (SOFT)., http://www.cancer.gov/clinicaltrials/view_clinicaltrials.aspx?version=healthprofessional&cdrid=318832

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.